A Randomized, Double Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys with Duchenne Muscular Dystrophy

Trial Profile

A Randomized, Double Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys with Duchenne Muscular Dystrophy

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 12 Nov 2018

At a glance

  • Drugs Talditercept alfa (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Therapeutic Use
  • Sponsors Bristol-Myers Squibb; Chugai Pharmaceutical; Roche
  • Most Recent Events

    • 10 Jul 2018 Planned End Date changed from 30 Jul 2020 to 17 Dec 2021.
    • 10 Jul 2018 Planned primary completion date changed from 30 Jul 2020 to 30 Dec 2020.
    • 03 May 2018 Status changed from active, no longer recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top